Premium
Alveolar Ridge and Maxillary Sinus Augmentation Using rh BMP ‐2: A Systematic Review
Author(s) -
Freitas Rubens Moreno,
SpinNeto Rubens,
Junior Elcio Marcantonio,
Pereira Luís Antônio Violin Dias,
Wikesjö Ulf ME,
Susin Cristiano
Publication year - 2015
Publication title -
clinical implant dentistry and related research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.338
H-Index - 85
eISSN - 1708-8208
pISSN - 1523-0899
DOI - 10.1111/cid.12156
Subject(s) - alveolar ridge , maxillary sinus , medicine , dentistry , dental alveolus , sinus (botany) , bone morphogenetic protein , ridge , dental implant , implant , surgery , paleontology , biochemistry , chemistry , botany , gene , biology , genus
Purpose The aim of this systematic review was to evaluate clinical and safety data for recombinant human bone morphogenetic protein‐2 (rh BMP ‐2) in an absorbable collagen sponge ( ACS ) carrier when used for alveolar ridge/maxillary sinus augmentation in humans. Materials and Methods Clinical studies/case series published 1980 through J une 2012 using rh BMP ‐2/ ACS were searched. Studies meeting the following criteria were considered eligible for inclusion: >10 subjects at baseline and maxillary sinus or alveolar ridge augmentation not concomitant with implant placement. Results Seven of 69 publications were eligible for review. rh BMP ‐2/ ACS yielded clinically meaningful bone formation for maxillary sinus augmentation that would allow placement of regular dental implants without consistent differences between rh BMP ‐2 concentrations. Nevertheless, the statistical analysis showed that sinus augmentation following autogenous bone graft was significantly greater (mean bone height: 1.6 mm, 95% CI : 0.5–2.7 mm) than for rh BMP ‐2/ ACS (rh BMP ‐2 at 1.5 mg/m L ). In extraction sockets, rh BMP ‐2/ ACS maintained alveolar ridge height while enhancing alveolar ridge width. Safety reports did not represent concerns for the proposed indications. Conclusions rh BMP ‐2/ ACS appears a promising alternative to autogenous bone grafts for alveolar ridge/maxillary sinus augmentation; dose and carrier optimization may expand its efficacy, use, and clinical application.